Nephrogenic systemic fibrosis (NSF) is nearly nine times more likely to occur among dialysis patients exposed to gadolinium-containing MRI contrast than in those not exposed, according to a report in the American Journal of Kidney Diseases (2008;51:966-975).
The findings are based on a study of 19 NSF cases and 57 matched controls (dialysis without NSF) by Alexander J. Kallen, MD, MPH, of the Centers for Disease Control and Prevention in Atlanta, and colleagues.
Continue Reading
Their analysis also showed that as the contrast dose increased, so did NSF risk. Moreover, gadodiamide was associated more strongly with NSF than gadoversetamide.
